Life sciences watches closely as Brexit negotiations loom
PM finally sets date for Brexit.
X
Life sciences watches closely as Brexit negotiations loom
https://pharmaphorum.com/news/life-sciences-watches-closely-brexit-negotiations-loom/
ema
Patient power in Europe – more work to be done
What the EMA and pharma can do to promote patient involvement in decision making.
Brexit could delay drug launches, former MHRA chief warns
Britain will be in “second or third tier” of drug launches, experts warn.
Could UK’s post-Brexit regulator evaluate value as well?
But longer-term benefits could include faster reimbursement decisions.
Hunt under pressure over plans to quit EMA
Britain could be in “second rank” of medicines access, warn MPs.
EU drug regulators concerned about Brexit impact
European regulators concerned over impact of EMA move.
Boehringer files Humira biosimilar in US and EU
New threat to AbbVie’s top-seller.
Fast-track appraisals and Managed Access Agreements
Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
High-value, high-cost drugs: how to pay for them
Experts call for urgent development of new drug funding mechanisms.